A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. We have two core franchises in neurological and rare diseases. Our neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). Our rare disease franchise is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Net product sales from these two commercial products totaled $1,071.5 million for 2025, compared with $957.8 million for 2024.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.1B | 958M | 726M | 517M | 484M |
| Net Income | 391M | 391M | 226M | -61M | -216M | -168M |
| EPS | $2.30 | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
| Free Cash Flow | 105M | 105M | 157M | 17M | -114M | -127M |
| ROIC | 30.6% | 39.9% | 703.3% | -14.7% | -45.9% | -28.7% |
| Gross Margin | 91.7% | 91.7% | 91.5% | 94.3% | 98.0% | 97.8% |
| Debt/Equity | 0.04 | 0.04 | 0.07 | 0.13 | 0.15 | 0.12 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 105M | 105M | 231M | -73M | -224M | -170M |
| Operating Margin | 9.8% | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% |
| ROE | 31.9% | 39.9% | 38.9% | -14.7% | -45.9% | -28.7% |
| Shares Outstanding | 170M | 170M | 167M | 166M | 161M | 160M |
ACADIA PHARMACEUTICALS INC passes 4 of 9 quality checks, suggesting mixed fundamentals.
ACADIA PHARMACEUTICALS INC trades at 9.6x trailing earnings, compared to its 15-year median P/E of 12.2x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 35.6x vs a median of 31.3x. The company's 5-year average gross margin is 94.6%. At current prices, the estimated annualized return to fair value is +66.3%.
ACADIA PHARMACEUTICALS INC (ACAD) has a current P/E ratio of 9.6, compared to its historical median P/E of 12.2. The stock is currently considered Cheap based on its historical valuation range.
ACADIA PHARMACEUTICALS INC (ACAD) has a 5-year average return on invested capital (ROIC) of -12.4%. This is below average and may indicate limited pricing power.
ACADIA PHARMACEUTICALS INC (ACAD) has a market capitalization of $3.7B. It is classified as a mid-cap stock.
ACADIA PHARMACEUTICALS INC (ACAD) does not currently pay a regular dividend.
Based on historical P/E analysis, ACADIA PHARMACEUTICALS INC (ACAD) appears cheap. The current P/E of 9.6 is 22% below its historical median of 12.2. The estimated fair value CAGR (P/E method) is 118.0%.
ACADIA PHARMACEUTICALS INC (ACAD) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ACADIA PHARMACEUTICALS INC (ACAD) reported annual revenue of $1.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
ACADIA PHARMACEUTICALS INC (ACAD) has a net profit margin of 36.5%. This is a strong margin indicating high profitability.
ACADIA PHARMACEUTICALS INC (ACAD) generated $105 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ACADIA PHARMACEUTICALS INC (ACAD) has a debt-to-equity ratio of 0.04. This indicates a conservatively financed balance sheet.
ACADIA PHARMACEUTICALS INC (ACAD) reported earnings per share (EPS) of $2.30 in its most recent fiscal year.
ACADIA PHARMACEUTICALS INC (ACAD) has a return on equity (ROE) of 39.9%. This indicates the company generates strong returns for shareholders.
ACADIA PHARMACEUTICALS INC (ACAD) has a 5-year average gross margin of 94.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for ACADIA PHARMACEUTICALS INC (ACAD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ACADIA PHARMACEUTICALS INC (ACAD) has a book value per share of $7.22, based on its most recent annual SEC filing.